Key facts
- It has raised $10.0M.
- Notable investors include Enterprise Ireland, MedTech Innovator, European Regional Development Fund (Brandenburg), IQ-EQ, Alpha Innotech — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Novus Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Novus Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Novus Diagnostics
Developer of a point-of-care diagnostic system designed to improve treatment of patients in the critical early stages of infection. The company's system combines novel electrochemical sensors, centrifugal microfluidics, and automated sample processing and analysis to diagnose and characterise a bloodstream infection within minutes, enabling healthcare providers to diagnose pathogens associated with sepsis from a blood sample and effectively treat patients at a lower cost.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2016
- Employees
- 20
- Website
- novus-dx.com/
- Ownership
- Privately Held (backing)
Novus Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Novus Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Novus Diagnostics in its N-PORT filings yet. We sweep new filings monthly.